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Gastric cancer is the second most common cancer in the world and the fifth leading cause of cancer-related death in Taiwan. To
improve the survival of gastric cancer patients, biomarkers for early detection and effective anticancer therapy are required. An
essential first step is to profile gene expression in gastric cancer and identify genes that are aberrantly expressed, and to do this cDNA
microarrays were performed. The clinic–pathologic correlation and prognostic significance of the aberrantly expressed genes were
evaluated to identify novel biomarkers of gastric cancer. Fresh surgical samples of tumour tissue and matching noncancerous mucosa
were obtained immediately after gastric resection in 43 patients. Secreted Protein, Acidic and Rich in Cysteine (SPARC)
(Osteonectins), one of the most highly expressed genes in both intestinal and diffuse gastric cancers in our microarray results, was
selected for further study. The overexpression of SPARC was verified using real-time quantitative-reverse transcription–polymerase
chain reaction (Q-RT–PCR), Northern blot and immunohistochemical staining. The expression of SPARC in tumour tissues was, on
average, 4.27-fold increased (95% CI 2.68–5.85) compared to adjacent noncancerous mucosa (Po0.001). The expression of SPARC
was higher in advanced (T2, T3 and T4) cancer compared to the early (T1) cancer (P¼0.048) with regard to depth of wall invasion.
Higher expression of SPARC was significantly associated with lymph node metastasis (Po0.001), lymphatic invasion (P¼0.004) and
perineural invasion (P¼0.047). Expression of SPARC in patients in stage II and above was significantly higher than those in stage I
(P¼0.017). The 3-year survival of patients with lower expression of SPARC was significantly better than those with a higher
expression (log rank P¼0.047). These data indicate the potential of SPARC as a prognostic marker for gastric cancer.
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Gastric cancer is the second most common cancer in the world,
while in Taiwan it is the fifth leading cause of cancer-related death.
Surgery remains the only cure for this disease. In a recent study,
more than 30% of surgical patients were too advanced to receive
curative resection (Wang et al, 2002). To improve the poor survival
outcome and permit earlier diagnosis, there is a need for new
prognostic indicators or tumour markers more sensitive than
those currently available, including CEA, CA19-9 and others
(Marrelli et al, 1999).
Histomorphologically, gastric cancer is divided into two main
types, ‘intestinal-differentiated’ and ‘diffuse-undifferentiated’
(Lauren, 1991; Tahara, 1993). However, lesions with a similar type
may differ in biological aggressiveness and response to therapy.
The molecular events for development and progression of gastric
cancer are a complex process involving multiple genes and
multiple steps, sequentially or in concert (Tahara, 1993). Several
risk factors including genetic alterations, chromosomal instability,
and Helicobacter pylori infection have been reported for gastric
cancer (Barreto-Zuniga et al, 1997; Yasui et al, 2001; Kim et al,
2003). Moreover, numerous biomarkers identified have contri-
buted to our knowledge of the molecular or cellular mechanisms of
gastric carcinogenesis and progression (Yasui et al, 2001). Most
biomarkers are prognostic factors used to indicate the groups of
patients at risk of relapse or metastasis (Allgayer et al, 1997).
However, useful biomarkers for early detection and therapy are
still lacking and depend on future studies. Gene expression
profiling offers a new approach for cancer diagnosis and may
contribute to our understanding and the future elucidation of a
cure (Pusztai et al, 2003; Ransohoff, 2003). To achieve these goals,
the relevant subsets of differentially expressed genes of interest
must be identified, cloned and studied in detail. Complementary
DNA (cDNA) microarrays are currently recognised as a powerful
technique to search for novel biomarkers through the establish-
ment of gene expression profiles (Ransohoff, 2003).
Using cDNA microarry, we identified a highly expressed gene
for gastric cancer, Secreted Protein, Acidic and Rich in Cysteine
(SPARC), also designated as osteonectin and BM40 (Motamed,
1999). SPARC is a single-copy gene mapped to mouse chromo-
some 11 and to the long arm of human chromosome 9 (Motamed,
1999). High conservation is observed between the bovine, mouse
and human SPARC sequences. The SPARC gene expresses a major
mRNA species 2.2kb in length, which is translated into a 43-kDa
Ca
2þ-binding glycoprotein. Initially in 1981, SPARC was described
as a bone matrix protein involved in bone mineralisation. Recent
studies have revealed other biological functions including cell
proliferation (Sage et al, 1995), migration, morphogenesis
(Strandjord et al, 1995), deadhesion, antiproliferation (Motamed,
1999; Bornstein and Sage, 2002), differentiation (Bassuk et al,
1999) and angiogenesis (Kupprion et al, 1998). SPARC was
reported to be overexpressed in a variety of human malignancies,
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yincluding melanoma, glioma, meningioma, colorectal, breast,
oesophageal, renal cell, prostate, bladder and hepatocellular
carcinoma (Porte et al, 1995; Le Bail et al, 1999; Massi et al,
1999; Menon et al, 2000; Takano et al, 2000; Thomas et al, 2000;
Sakai et al, 2001; Yamanaka et al, 2001; Iacobuzio-Donahue et al,
2002; Yamashita et al, 2003). However, SPARC was repressed in
ovarian cancer (Paley et al, 2000).
Overexpression of the SPARC gene was observed in human
gastric cancer in two other reports (Wewer, 1988, Maeng et al,
2002b). However, both studies had no detail in clinic–pathologic
correlation. Overexpression of SPARC gene was also observed in
gastric adenocarcinomas and adenomas induced by a chemical
carcinogen (N-methyl-N0-nitro-N-nitrosoguanidine) in Lewis and
WKY rats (Maeng et al, 2002a). It implied that SPARC expression
appeared in the initiation stage of experimental gastric carcino-
genesis (Maeng et al, 2002a).
The aim of this study was to identify useful biomarkers using
cDNA microarrays, and to investigate their clinical significance in
gastric cancers. We found that SPARC expression was significantly
higher in the advanced stage of gastric cancer in comparison to the
early stage, indicating SPARC potential as a marker for the more
advanced forms of gastric cancer.
MATERIALS AND METHODS
Between September 2000 and November 2001, a total of 43 patients
with gastric cancer entered this study. They included 24 male and
19 female patients. The median age was 61 years (range 35–83). All
patients had undergone gastric resection including 16 total
gastrectomies and 27 subtotal gastrectomies.
Clinic–pathologic studies
Re-sected specimens were studied pathologically according to the
criteria described in the Japanese General Rules for Gastric Cancer
Study (Japanese Gastric Cancer, 1998) and the UICC pTNM
classification (Sobin and Fleming, 1997). The study items included
age, gender, tumour location, tumour size, gross (Borrmann) type,
wall invasion, resection margin, histologic type, lymph node
metastasis, vascular invasion, lymphatic invasion and perineural
invasion. The histological features were classified into two types:
(1) intestinal or differentiated type, consisting of papillary and/or
tubular adenocarcinomas and (2) diffuse or undifferentiated type,
consisting of poorly differentiated, signet-ring cell, and/or
mucinous adenocarcinomas (Japanese Gastric Cancer, 1998;
Tahara, 1993). After discharge, all patients received periodic
follow-up in the outpatient department until the time of writing, or
until their death.
Tumour samples
Fresh samples of both tumour tissue and adjacent noncancerous
mucosa were obtained immediately after gastric resection. The
samples were carefully dissected from resected specimens by a
pathologist, and immediately snap frozen in separate vials using
liquid nitrogen. These frozen specimens were stored at  701Ci na
tumour bank until use.
cDNA microarray analysis
Specimens were taken from fresh surgical samples of tumour
tissue and matching normal mucosa, stored in a  701C tumour
bank. For fluorescence labelling of cDNA, 30mg of total RNA from
tumour cells and 50mg of total RNA from normal mucosa cells
were reverse transcribed in the presence of Cy3-dUTP and Cy5-
dUTP (Amersham Inc., Piscataway, NJ, USA), respectively.
Labelled cDNA was purified and resuspended in the hybridisation
buffer as described (Eisen and Brown, 1999). For the duplication
experiment, we switched the Cy3-dUTP and Cy5-dUTP labelling to
the normal and tumour cells RNA, respectively. Human Universo-
Chip 8K cDNA arrays (Asia Bio-Innovations Corporation, Taipei,
Taiwan), containing 7597 genes (cDNAs), were used to distinguish
the specific gene(s) that were overexpressed or underexpressed in
five pairs of human gastric specimens. Hybridised slides were
scanned using the GenePix 4000B scanner (Axon Instrument, CA,
USA) and images were processed using the GenePix Pro 3.0 (Axon
Instrument). Microarray data were analysed using the eGenomix
V1.0 (Asia BioInnovations Corporation, Taipei, Taiwan) and
EXCEL (Microsoft, Seattle, WA, USA) software. Both samples
and genes were classified by a two-way clustering analysis to
identify genes that were differentially expressed between cancer
and nontumorous tissues.
Among the differentially expressed genes, those that were highly
upregulated in both histological types of tumour were selected for
further confirmational study including Northern blot analysis,
real-time Q-RT–PCR and immunohistochemistry.
Northern blot analysis
Equal amounts of total RNA (20mg) were analysed on a 1.2%
agarose-formaldehyde gel. The RNA was then blotted onto a
nitrocellulose membrane and subjected to Northern blot analysis
(Lin et al, 2002). A a
32P-dCTP-labeled random-primed probe
(3000Ci/mmol; Amersham) was hybridised to the membrane. The
probe was a full-length SPARC cDNA fragment, which was amplified
by the PCR. Membranes were subsequently reprobed with a
a
32P-labelled glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA fragment to verify an equal application of RNA to each lane.
Real-time quantitative-reverse transcription–polymerase
chain reaction
Total RNA was extracted from cells using Trizol. Subsequently, the
first strand of cDNA was synthesised using the Superscript III kit
for RT–PCR (Life Technologies, Rockville, MD, USA). Briefly,
total RNA was denatured at 651C for 5min in the presence of 0.5mg
oligo dT and 1mM dNTP. After chilling on ice for at least 1min, RT
was allowed to proceed at 251C for 5min in the presence of 1 
first-strand buffer, 5mM DTT and 40 units of RNase inhibitor. The
reaction was then allowed to proceed at 501C for another 60min.
The reaction was terminated by heat inactivation at 701C for
10min. Real-time Q-RT–PCR was performed in a 25ml reaction
mixture containing 50nM forward and reverse primers, 1X SYBR
green reaction mix (Applied Biosystems, Werrington, UK) and
various amounts of template. The reaction was performed with
preliminary denaturation for 10min at 951C to activate Taq DNA
polymerase, followed by 40 cycles of denaturation at 951C for 15s,
and annealing/extension at 601C for 1min. Fluorescence emitted
by SYBR green was detected by the ABI PRISM 7000 sequence
detection system (Applied Biosystems). The primers are forward,
5-CCTGGAGACAAGGTGCTAACAT-3 and reverse, 5-CGAGTTCT
CAGCCTGTGAGA-3. Different amounts of template (16, 8, 4, 2,
1ng) were used in the same reaction to ensure linear amplification.
All PCR reactions were performed in duplicate on the same 96-well
plate. 18S RNA was used as an internal control amplified in the
same PCR reaction and expressed as 2
 DCt k, where k is a
constant and  DCt is Ct(sparc gene) Ct(18S). Ct is defined as the cycle
at which fluorescence is determined to be statistically significant
above background. The expression of a specific gene in the tumour
tissue was determined using the fold of activation over the
matching noncancerous mucosa.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were examined by
immunohistochemistry using the avidin–biotin complex (ABC)
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ymethod (Hsu et al, 1981). A tissue block that included both benign
gastric mucosa and an area of carcinoma was chosen from each
patient. They were sectioned into 4-mm-thick slides and the
paraffin removed. After antigen retrieval, tissue sections were
stained with 1:50 dilution of anti-SPARC monoclonal antibody
(ZYMED lab, CA, USA). The staining process was automated and
performed on a Ventana immunostainer. A normal skin sample
was included in each assay as a positive control (Hunzelmann et al,
1998), and staining without primary antibody was used as a
negative control. Cytoplasmic patches of brown colour were scored
as SPARC positive. The interpretation of the benign gastric mucosa
was based on staining results of the superficial epithelium only,
because the parietal cells and chief cells of gastric pits are normally
stained strongly with SPARC. Comparisons were made between the
intensity of the staining of the carcinoma cells and benign
superficial epithelium on the same slide. The negative group
consisted of cancer cells with no detectable ( ) or only trace
staining of SPARC immunoreactivity (þ1). The positive group
consisted of cancer cells with moderate (þ2) or high levels (þ3)
of SPARC immunoreactivity.
Statistical analysis
When appropriate, the Mann–Whitney U-test or Fisher’s exact test
was used for between-group comparisons. The relationship
between the results of two different examinations was analysed
by Spearman’s correlation test. Follow-up of the patients was
carried out until the time of writing or until the patient died. The
cancer-specific survival outcome was expressed by applying the
Kaplan–Meier method for all patients excluding those who died
from surgical complications. The log-rank test was used to compare
the prognostic significance of individual variables on survival. Cox’s
proportional hazards model was used in a multivariate analysis to
identify the independent predictors of survival. A P-value of o0.05
was considered statistically significant.
RESULTS
Clinical characteristics of the patients
Characteristics of all patients included in this study are listed in
Table 1. The mean tumour size (maximal diameter) was
4.873.2cm (median 3.5cm, range 0.9–18cm). The tumours were
located in the proximal third of the stomach in nine cases, the
middle third in 13, the distal third in 20 and the whole stomach in
one. The histological types consisted of intestinal type in 16 and
diffuse type in 27 patients. As defined by the depth of wall
invasion, early gastric cancer (T1) was noted in 10 (23.3%) cases
(mucosa in four and submucosa in six), while advanced cancer
included T2 (muscle proper and subserosa) in four, T3 (serosa) in
25 and T4 (invasion to adjacent organs) in four. Lymph node
metastasis was found in 32 cases (74.4%). During operation,
peritoneal seeding was found in seven (16.3%) and no liver
metastasis was noted in any of our patients. The pathologic stage
was distributed as IA in six, IB in five, II in four, IIIA in seven, IIIB
in nine and IV in 12.
Results of cDNA microarray
Microarray results were obtained from five pairs of specimens
(tumour tissue and adjacent non-tumorous mucosa) of both
intestinal and diffuse histological types in duplicate. There were
more than 2.8% (216/7597) distinct genes either upregulated
(ratio42) or downregulated (ratioo0.5) in these array experi-
ments. The numbers of highly upregulated genes were 86 in the
intestinal type and 138 in the diffuse type (data not shown). Tables
2 and 3 outline the top five most overexpressed genes for the
intestinal and diffuse types, respectively. Among them, SPARC was
the most highly expressed gene in the diffuse type and the second
most highly expressed in the intestinal type of gastric cancer.
Therefore, SPARC was selected for further study.
Verification of the abundance of SPARC mRNA in gastric
cancer tissues
Real-time Q-RT–PCR data for the expression of SPARC were
measured by the ratio of SPARC signal in tumour tissue to that in
noncancerous adjacent tissues. The mean expression of SPARC
was 4.27-fold increased in tumour tissues, as compared to normal
Table 1 Correlation between patient’s demographic characteristics and
the expression level of SPARC measured by Q-RT–PCR
Parameters No. SPARC (mean7s.e.) P-value
Age (years)
o64 22 3.7271.10 0.653
X65 21 4.8671.21
Gender
Male 24 3.7770.94 0.874
Female 19 4.9371.34
Location
Proximal 9 5.3271.82 0.228
Middle 13 2.3070.66
Distal 20 5.3171.36
Size (cm)
p2.5 12 2.2070.71 0.165
42.5 31 5.0871.02
Gross type
Borrmann 0–2 12 2.3270.81 0.108
Borrmann 3–4 31 5.0471.02
Histology
Intestinal 16 3.8970.90 0.624
Diffuse 27 4.5171.14
Depth of wall invasion
Early (T1) 10 1.8170.69 0.048
Advanced (T2–4) 33 5.5670.97
Lymph node metastasis
Negative 11 0.8070.16 o0.001
Positive 32 5.4870.97
Distant metastasis
M0 30 3.8970.80 0.488
M1 13 5.1971.87
Pathologic stage
Stage 1 11 1.6770.63 0.017
Stage 2–4 32 5.1870.99
Vascular invasion
Negative 37 4.0770.77 0.824
Positive 6 5.5973.26
Lymphatic invasion
Negative 15 1.6570.50 0.004
Positive 28 5.6971.09
Perineural invasion
Negative 29 3.4870.86 0.047
Positive 14 5.9371.58
Peritoneal seeding
Negative 36 4.7370.91 0.508
Positive 7 1.9970.60
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(Po0.001, by one-sample T-test). The patients were divided into
two groups according to the ratio of SPARC expression in the
tumour samples, as compared to the adjacent normal tissue. There
were 12 (28%) patients in the lower expression groups (p1.0-fold),
and 31 (72%) patients in the higher expression groups (41.0-fold).
The real-time Q-RT–PCR assay yielded very reproducible results
that supported the microarray data.
We further confirmed the SPARC expression levels in several
patients by Northern blot analysis. Figure 1 illustrates SPARC
expression in several representative patients. A 2.2-kb SPARC
transcript was detected in all cancer tissues examined. The cancer
tissues from both intestinal (G10, G20, G24) and diffuse (G25, G27,
G40) types all highly expressed SPARC compared to the matched
noncancerous adjacent mucosa (Figure 1A and B). The Northern
blot analysis determined the mean expression of SPARC in cancer
tissues was 4.7-fold (range 1–12) greater than in their noncancer-
ous counterpart, which confirmed the trend observed in the real-
time Q-RT–PCR.
Overexpression of SPARC protein in gastric cancerous
tissues demonstrated by immunostaining
To investigate the expression and location of SPARC in tissues,
immunostaining was performed on gastric cancer tissues and
matched noncancerous muscosa. Figure 2B shows a diffuse-type
and Figure 2D an intestinal-type tumour. In contrast, Figure 2A
and C are their normal counterparts. The immunostaining was
most marked (dark brown colour) in the cancer cells, and low
levels were observed in the stroma cells or fibroblasts in gastric
cancer tissues. Weak staining was observed for SPARC in the
Table 2 The five most highly overexpressed genes in the intestinal type
of gastric cancer tissues by cDNA microarray
Name
Accession
no. UG_LINK Symbol Function
Fold
activation
Immediate early
response 3
AA480815 Hs.76095 IER3 Apoptosis 6.58
Secreted protein,
acidic, cysteine-rich
(osteonectin)
H95960 Hs.111779 SPARC Binding protein/
calcium/collagen
6.53
Protective
protein for
beta-galactosidase
(galactosialidosis)
AA916327 Hs.118126 PPGB m-esterase/
m-deamidase
6.28
Human secretory
protein (P1.B)
mRNA,
complete cds
N74131 Hs.82961 Cell matrix
protein/cell
adhesion
5.87
Myosin regulatory
light chain,
complete cds
AA487370 Hs.180224 Apoptosis 5.56
Table 3 The five most highly overexpressed genes in the diffuse type of
gastric cancer tissues by cDNA microarray
Name
Accession
no. UG_LINK Symbol Function
Fold
activation
Secreted protein,
acidic, cysteine-rich
(osteonectin)
H95960 Hs.111779 SPARC Binding
protein/
calcium/
collagen
9.68
Interferon-inducible AA862371 Hs.182241 1-8D Surface
molecule
9.16
Collagen, type III,
alpha 1
T98612 Hs.119571 COL3A1 Structure
protein
7.62
Carcinoembryonic
antigen-related cell
adhesion molecule 5
AA130584 Hs.118778 CEACAM5 Antigen 7.42
Ribosomal
protein L39
N76229 Hs.177461 RPL39 Structure
protein/
protein
synthesis
6.16
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Figure 1 Overexpression of SPARC in gastric carcinoma. (A) Northern
blot analysis revealed a 2.2-kb SPARC transcript in cancer tissues examined
from our surgical specimens. SPARC is overexpressed in all tumour tissues
(T) compared to the matched noncancerous adjacent mucosa (N). G10,
G20 and G24 are intestinal tumour samples, while G25, G27 and G40 are
diffuse-type of tumours. (B) The intensities of SPARC expression on the
blots shown in (A) were quantified, and the extent of activation of SPARC
expression was determined at each time point. Fold activation indicates the
ratio of SPARC signal in tumour to that in normal adjacent tissue. Data are
means7s.e. of values from three independent experiments.
Figure 2 Immunohistochemical staining of SPARC expression in two
(G25 and G20) representative human gastric cancer tissues and matching
noncancerous mucosa. G25 and G20 are diffuse-type gastric cancer and
intestinal-type gastric cancer, respectively. (A) G25 noncancerous mucosa,
(B) G25 diffuse-type gastric cancer, (C) G20 noncancerous mucosa, (D)
G20 intestinal-type gastric cancer. Positive staining of SPARC is indicated by
a dark brown colour. The SPARC expression was stained mainly in the
gastric cancer cells, and less intensively in the stroma cells.
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ynormal gastric epithelial cells (Figure 2A and C). Only a trace of
immunoreactivity was distinguished in the adjacent noncancerous
mucosa (Figure 2A and C). Among the 40 patients studied by
immunohistochemistry, the intensity of immunostaining in
tumour tissue was determined as 1þ in 15 patients (37.5%),
2þ in 19 (47.5%) and 3þ in 6 (15%). The higher expression
group (2þ and 3þ) accounted for 62.5% (25/40). In contrast, the
intensity of immunostaining in nontumorous mucosa was 1þ in
35, and 2þ in five. Furthermore, the immmunoreactivity in the
cancerous tissues was greater than in the nontumorous counter-
part in 23 patients, and equal in 17. The SPARC expression levels
in tumour tissue, as determined by immunohistochemistry, was
comparable to that ascertained by real-time Q-RT–PCR (Pearson’s
correlation coefficient¼0.421; P¼0.008).
SPARC expression and clinic–pathologic correlation
SPARC expression in tumour tissue was not significantly
associated with age, gender, tumour location, tumour size, gross
type or histological type (Table 1). Higher levels of SPARC were
noted in advanced (T2, T3 and T4) cancer compared to the early
(T1) cancer (P¼0.048) with regard to depth of wall invasion
(Figure 3A). Higher expression of SPARC was significantly
associated with lymph node metastasis (Po0.001) (Figure 3B),
lymphatic invasion (P¼0.004) and perineural invasion
(P¼0.047). It was not associated with vascular invasion or
peritoneal seeding. Expression of SPARC in patients with
pathologic stageXII was significantly higher than those with stage
I( P¼0.017) (Figure 3C).
Survival outcome
The mean duration of the follow-up period for survivors (n¼26)
was 30.5. months (range 20–43 months). In all, 17 patients
died as a result of the progression of gastric cancer, and another
patient died due to surgical complications. The overall cumulative
3-year survival rate of the 43 patients with gastric resection
was 53.9%. Figure 4 illustrates the cumulative survival curves
of patients divided into the lower expression (n¼12) and
higher expression (n¼31) groups of SPARC. The lower expression
group was defined as those with equal or lower (p1.0-fold)
SPARC expression in the tumour, whereas the higher expression
group consisted of patients expressing higher levels (41.0-fold)
of SPARC in the tumour than in the adjacent normal tissue,
as determined by real-time Q-RT–PCR. The 3-year survival
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Figure 3 Scatterplots of comparison between the activation of SPARC and various clinicopathological features according to: (A) depth of wall invasion
(P¼0.048, T1 vs T2–4); (B) status of lymph node metastasis (Po0.001, N0 vs N1–3); (C) pathologic stage (P¼0.017, stage I vs stage II–IV).
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Figure 4 The Kaplan–Meirs survival curves of two groups of gastric
cancer patients defined by a SPARC expression level cutoff value of 1.0, as
determined by real-time Q-RT–PCR. The 3-year survival rate of the low
expression group (p1.0-fold) in our patients was significantly better than
that of the higher expression groups (41.0-fold, 80.8 vs 43.7%; log rank
P¼0.047).
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yrate of the low expression group in our patients was significantly
better than that of the higher expression groups (80.8 vs 43.7%; log
rank P¼0.047) (Figure 4).
Univariate analysis showed that other significant prognostic
factors included the status of lymph node metastasis (N0/N1, N2,
N3; log rank Po0.0001), serosal invasion (positive/negative; log
rank P¼0.0145), lymphatic invasion (positive/negative; log rank
P¼0.0007), peritoneal seeding (positive/negative; log rank
P¼0.0003), perineural invasion (positive/negative; log rank
P¼0.0014) and tumour size (p4cm/4 4cm; log rank
P¼0.0006). Multivariate analysis revealed that the status of lymph
node metastasis was the only significant prognostic factor for the
survival of the patients (Figure 4).
DISCUSSION
In this study, SPARC was identified, by cDNA microarray, as one
of the most overexpressed genes in more than 60% of the gastric
cancer patients included in this study. The overexpression of
SPARC was verified by Northern blot analysis, real-time Q-RT–
PCR and immunohistochemistry. Therefore, cDNA microarrays
are a useful way to perform a large-scale analysis of the expression
level of thousands of genes simultaneously (Schena et al, 1995).
When used for studies on clinical samples, of normal vs diseased, it
may lead to the identification of novel biomarkers for these
diseases (Zweiger, 1999). The biomarkers may be candidates for
establishing early diagnosis and designing therapeutic targets for
specific diseases or cancers.
In the patients examined here, higher SPARC expression was
significantly associated with tumour progression (lymph node
metastasis, lymphatic and perineural invasion) and the advanced
stages of gastric cancer. In addition, patients with lower SPARC
expression had an improved prognosis. A similar clinic–
pathologic relationship between SPARC expression and tumour
progression has been reported in other malignancies (Porte et al,
1995; Massi et al, 1999; Thomas et al, 2000; Sakai et al, 2001;
Yamanaka et al, 2001; Yamashita et al, 2003). The expression of
SPARC has been positively correlated with the histological grade of
tumour cells in bladder cancer, thyroid cancer, glioma and HCC
(Le Bail et al, 1999; Menon et al, 2000; Takano et al, 2000;
Yamanaka et al, 2001). Higher SPARC expression was also
associated with local tumour invasion in colorectal, breast, bladder
and renal cell carcinoma (Porte et al, 1995; Sakai et al, 2001;
Yamanaka et al, 2001; Iacobuzio-Donahue et al, 2002). Increased
levels of SPARC were associated with lymph node metastasis in
colorectal and oesophageal cancers, liver metastasis in colorectal
cancer and bone metastasis in prostate cancers (Porte et al, 1995;
Thomas et al, 2000; Yamashita et al, 2003). In addition, high
SPARC expression was associated with poor prognosis and
survival in colorectal cancer, melanoma and oesophageal cancer
(Porte et al, 1995; Massi et al, 1999; Thomas et al, 2000). However,
the expression is inversely correlated with the degree of ovarian
malignancy, where the downregulation of SPARC is essential for
carcinogenesis (Paley et al, 2000).
The cellular origin of SPARC is variable among malignant
tumours. SPARC may be expressed predominantly either in the
tumour cells or in the stromal cells depending on the types of
malignancies. The protein immunoreactivity of SPARC was
detected mainly in the stroma cells, but rarely in the tumour cells
in malignant ovaries, colorectal cancer, breast cancer and
hepatocellular carcinoma (Porte et al, 1995; Le Bail et al,
1999; Paley et al, 2000; Iacobuzio-Donahue et al, 2002). The
signals originating from tumour cells regulate SPARC expression
in neighbouring fibroblasts. When SPARC is secreted from
stroma cells, it exerts its role on neoplastic progression
in a paracrine fashion (Porte et al, 1995; Le Bail et al, 1999). In
contrast, immunostaining for SPARC was located mainly in
the tumour cells in melanoma cells and oesophageal cancer
(Massi et al, 1999; Yamashita et al, 2003). In the gastric cancer
patients included in this study, the SPARC expression was
similar to that of oesophageal cancer, detected mainly in the
gastric cancer cells, and less intensively in the stroma cells. Our
finding was similar to that in one report on gastric cancer study
(Wewer et al, 1988), but different from another report, where
SPARC stained only the stroma cells in gastric cancer tissues
(Maeng et al, 2002b).
Invasion and metastasis are the inherent characteristics of
malignant diseases and involve both intercellular and cell–matrix
interactions. The molecular mechanisms include the transcrip-
tional modulation of adhesive and antiadhesive molecules,
proteases and angiogenic factors. It has been suggested that
SPARC may play a key role during the initial steps in the process of
tumour invasion and metastasis (Porte et al, 1995). One of
SPARC’s biological functions is the modulation of angiogenesis
(Lane et al, 1994). It may promote neo-vascularisation, invasion
and metastasis of human malignancies (Motamed, 1999; Paley et al,
2000; Thomas et al, 2000; Sakai et al, 2001). Furthermore, SPARC
has demonstrated antiadhesive properties and displayed dimin-
ished adhesive interactions between tumour cells and the
extracellular matrix via the reduction of cell–substrate contacts
and the promotion of cytoskeletal rearrangement (Ledda et al,
1997). The antiadhesive properties of SPARC facilitate the invasion
and metastasis of tumour cells (Thomas et al, 2000). In addition,
SPARC can induce the expression of metalloproteinases or
enzymes that subsequently play an important role in the
degradation of basal membranes and extracellular matrix compo-
nents (Tremble et al, 1993). A significant correlation with MMP-2
gene expression implies that the regulation of MMP-2 may be a
possible mechanism underlying the effect of SPARC on the
progression of oesophageal and bladder cancer (Ledda et al,
1997; Thomas et al, 2000; Yamanaka et al, 2001; Yamashita et al,
2003).
Our work defines the mis-regulation of SPARC in gastric
carcinoma and its strong association with the more advanced
stages of this disease. The overexpression of SPARC in a variety of
malignancies excludes it as a suitable diagnostic biomarker for any
specific tumour, although it displays promise as a prognostic
marker of tumour progression and advanced cancer stage. We had
analysed the serum SPARC expression in 20 gastric cancer patients
by the Western blot. However, we did not detect the expression of
SPARC under our experimental condition (data not shown).
However, the serum concentration of SPARC had been detected
by a sandwich ELISA method in the type II diabetes mellitus
patients (Kanauchi et al, 2000). Whether determination of the serum
SPARC level can be used in clinical diagnosis awaits further study.
The identification of the molecular determinants of invasion and
metastasis will guide the development of new therapies. Two recent
in vitro studies delineate the potential of SPARC as a suppressor of
tumorigenic potential in human melanoma and breast cancer cells
via the addition of either antisense RNA or the transfection of
SPARC (Ledda et al, 1997; Dhanesuan et al, 2002). Finally, our
study demonstrates that the further investigation of SPARC is
warranted due to its status as a potential prognostic and
therapeutic agent.
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